Bellen Completes Series D+ Financing Led by Honghui Capital to Advance CRO/CDMO and Small Molecule Drug Discovery Platform
VCBeat has learned that in August 2020, Bellen (Ningyuan) Group swiftly completed its Series D+ financing round. The round was led by HighLight Capital, with participation from Yantai Jinye and Kunlun Capital. The funds will continue to be used to advance the company’s CRO/CDMO business and to build a one-stop service platform for chemical synthesis in small-molecule new drug R&D.
Since 2016, the company has completed four rounds of financing over a four-year period, garnering favor from more than ten investment funds, including Tsinghua Holdings Yinxing, Teyi Ventures, Legend Capital, CICC Qichen, Fortune Capital, Xingze Capital, China Merchants Capital, Sherpa Fund, Huagai Capital, Zhongding Capital, Boxing Capital, and Jianggu Capital. The recent D+ round further secured investments from Honghui Capital, Yantai Jinye, and Kunlun Capital, highlighting the strategic focus of various capital players on the CRO/CDMO sector and reflecting the capital market’s affirmation of the company’s development. This financing round serves as an exemplary case of investment-service synergy, further expanding the company’s strategic resources. Moving forward, the company will remain steadfast in its mission, continuing to deepen its expertise in chemical synthesis within the CRO/CDMO field and sparing no effort to contribute to global new drug research and development.
Jiang Yanye, spokesperson for Honghui Capital, stated, “We are honored to join the ranks of those supporting the sustained development of Bellen Chemistry. The Bellen team, led by Mr. Liu Bo, demonstrates strong professional expertise, execution capabilities, and cohesion. With the completion of the new base, we will be able to provide high-quality integrated services to more pharmaceutical R&D enterprises, thereby fulfilling our long-term strategic objectives.”
Bellen (Ningyuan) Group was founded in 2010 by six individual investors. The company specializes in contract research and development outsourcing (CRO) and contract development and manufacturing outsourcing (CDMO) for the chemical synthesis of high-end pharmaceutical intermediates, committed to building a globally leading one-stop service platform for the chemical synthesis of small-molecule new drug R&D.
After years of accumulation, the company has expanded its business from CRO to CDMO. It operates an early-stage R&D laboratory in Beijing, a process development center in Shanghai, and a production base covering nearly 100 mu in Yantai, Shandong Province. Additionally, it has established marketing and sales centers in France, Canada, the United States, the United Kingdom, and Japan, completing its group-wide and global layout. The company’s R&D services cover the entire value chain, including candidate molecule development, manufacturing process development, industrialization, and large-scale commercial contract manufacturing of pharmaceuticals, forming a professional one-stop service platform.
Leveraging its robust innovation capabilities, international team and global perspective, advanced management philosophy and awareness, comprehensive quality management and EHS (Environment, Health, and Safety) systems, as well as over a decade of accumulated expertise in the field of new drug R&D services, Bellen continues to provide high-quality services to renowned pharmaceutical companies and drug research institutions worldwide, while progressively establishing comprehensive strategic partnerships with an expanding client base.
Honghui Capital (HLC) is an investment firm focused on the “Healthy Living” sector, dedicated to serving leading enterprises that provide technological products and differentiated services for human disease diagnosis and treatment as well as healthy living. HLC has in-depth research and practical experience in bioengineering, medical devices, diagnostic equipment, personal care, and healthcare. The firm manages dual-currency funds in RMB and USD, with total assets under management exceeding RMB 10 billion. Its portfolio includes high-quality investments such as Mindray Medical, WuXi AppTec, Tigermed, Pharmaron, Yuwell Medical, United Imaging Healthcare, BrightGene, ZENTALIS, Genetron Health, Kintor Pharmaceutical, Sansure Biotech, Joinn Laboratories, Keming Diagnostics, SMOL, BEABA, and Nayuki’s Tea.